Article
X-GEN receives approval for drug
X-GEN Pharmaceuticals Inc. will begin marketing injectable acetazolamide for indications including open-angle glaucoma, secondary glaucoma, and preoperative use for the treatment of acute angle-closure glaucoma.
Key Points
Big Flats, NY-X-GEN Pharmaceuticals Inc. will begin marketing injectable acetazolamide for indications including open-angle glaucoma, secondary glaucoma, and preoperative use for the treatment of acute angle-closure glaucoma.
A commercially available brand is equivalent (Diamox, Duramed Pharmaceuticals), according to the company. Each vial contains acetazolamide sodium equivalent to 500 mg of acetazolamide in the form a sterile, preservative-free lyophilized powder.
"Currently, there is only one supplier of acetazolamide for injection USP," said Susan Badia, X-GEN president and chief executive officer. "Our launch of this product will ensure consistent supply and steady, competitive price levels."
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
